Gamma Medica, Inc. is a womens health company focused on overcoming the critical shortcomings of mammography and other screening modalities in the early detection of breast cancer. Part of the orginal firm founded in 1996, was involved in SBIR that year and very scative in the SBIR space. In 2011, the firm fell victim to tough times and in March 2013, the key technology and business focus of the firm was acquired through Chapter 11 sale and relocated to New Hampshire. The firm was able to raise $16M in new financing and retained some of former supporters The companys LumaGEM® MBI system is a commercially available, FDA-cleared, fully solid-state digital imaging system utilizing dual-head Digital Direct Conversion Gamma Imaging (DDCGI) technology for molecular breast imaging. With over 90 percent sensitivity and specificity, LumaGEM MBI has been shown to significantly improve cancer detection in women with dense breast tissue with fewer false positives relative to anatomical imaging technologies, such as MRI and whole breast ultrasound.
